Optomed Q2: Initial take – Softer sales than expected, but costs in line - Redeye

Redeye provides an initial take following the release of Optomed’s Q2 2025 report. Q2 sales fell short of our expectations, with the Devices segment contributing less than anticipated. We expect to make some downward revisions to our sales forecasts. Given the report, we anticipate a negative market reaction, with the share likely to decline by around 5–10% today.

Länk till analysen i sin helhet: https://www.redeye.se/research/1121494/optomed-q2-initial-take-softer-sales-than-expected-but-costs-in-line?utm_source=finwire&utm_medium=RSS